**Supplementary Table 2 List of the Products:** Top 10 Medicines in 2015 - 2017

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Active Ingredient | Total Cost (€) 2017 | Total Cost (€) 2016 | Total Cost (€) 2015 | List Price (€) Per Package as of 2017 | Licenced (Yes/No/ Applied) | Indication |
| Eculizumab 10 MG/ML | 149.631.305 | 138.948.808 | 100.659.000 | 4.881,22 | Yes (2015) | Paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome |
| Galsufase 1mg/5ml 1 Vial | 56.562.815 | 55.192.741 | 34.092.690 | 1.671,95 | Applied | Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) |
| Elosulfase Alfa 5mg/5ml 1 Vial | 39.219.814 | 36.787.009 | 24.069.825 | 998,69 | No | Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome) |
| Idursulfase 6mg/3ml Vial | 37.636.023 | 33.889.546 | 19.994.202 | 3.282,21 | No | Mucopolysaccharidosis II (Hunter syndrome) |
| Nusinersen\* | 37.000.000 | 30.450.838 | 17.114.040 | 90.000,00 | No | Spinal Muscular Atrophy |
| Defibrotide 200mg 10 Vial | 31.721.319 | 22.704.633 | 16.031.840 | 3.074,60 | No | Hepatic veno-occlusive disease. (VOD) |
| Alglucosidase Alfa 50mg 1 Vial | 25.151.199 | 7.045.481 | 11.874.835 | 493,74 | Applied | Pompe disease (acid α-glucosidase (GAA) deficiency). |
| Levodopa and Carbidopa Monohydrate (Intestinal Gel) | 9.205.134 | 6.803.361 | 9.886.075 | 847,38 | Yes (2012) | Advanced levodopa-responsive Parkinson's disease |
| Trientine Hydrochloride 250mg 100 tablet | 8.380.384 | 6.427.377 | 9.759.468 | 1.963,71 | No | Wilson Disease |
| Bacillus Calmette-Guerin (BCG) Vaccine 40mg/ml 1 Vial | 8.141.003 | 6.000.884 | 9.170.560 | 140,27 | No | Malign neoplasm of bladder |
| **Total** | **402.648.996** | **344.250.683** | **252.652.536** |  |  |  |

\*SSI has confidential agreement for Nusinersen and a part of product brought by SSI. Sales data shown here only represents products bringing via Turkish Pharmacists Association.